Platelets News and Research

RSS

NSVascular signs exclusive license with UCLA for Thin-Film Nitinol technology

NeuroSigma, Inc., a Los Angeles-based medical device company, today announced the formation of a majority owned subsidiary, NSVascular, Inc. and the signing of an exclusive license with the University of California, Los Angeles (UCLA) covering its medical applications of Thin-Film Nitinol (TFN) technology. Nitinol is a superelastic nickel and titanium alloy with unique properties that allow deformation and subsequent full recovery of the original shape upon exposure to body heat.

18 Jul 2011

Study shows benefits of onion waste on human health

More than 500,000 tonnes of onion waste are thrown away in the European Union each year. However, scientists say this could have a use as food ingredients. The brown skin and external layers are rich in fibre and flavonoids, while the discarded bulbs contain sulphurous compounds and fructans. All of these substances are beneficial to health.

14 Jul 2011

American Red Cross acquires HemaCare's red blood cell collection operation assets

HemaCare Corporation announced today that it has reached a definitive agreement to sell certain assets of its Blood Services operations to the American Red Cross. Under the terms of the sale, which closed today, HemaCare sold its red blood cell collection operation assets to the American Red Cross. The sale does not include HemaCare's platelet collection business.

11 Jul 2011

MicroOCT technology can reveal cellular features of coronary artery disease

Researchers at the Wellman Center for Photomedicine at Massachusetts General Hospital (MGH) have developed a one-micrometer-resolution version of the intravascular imaging technology optical coherence tomography (OCT) that can reveal cellular and subcellular features of coronary artery disease.

11 Jul 2011

Common cell pathway could lead to new treatments for autoimmune diseases and cancer

A discovery by University of Alabama at Birmingham researchers about a how a common cell pathway that helps regulate cell survival and production is turned on could lead to new treatments for autoimmune diseases and cancer.

8 Jul 2011

Transplants with half-matched bone marrow or cord blood are comparable to fully matched tissue

Identifying a suitable donor for leukemia and lymphoma patients who need bone marrow transplants may be far easier now that results of two clinical trials show transplant results with half-matched bone marrow or umbilical cord blood are comparable to fully matched tissue, thanks in large part to the availability of effective antirejection drugs and special post-transplant chemotherapy.

8 Jul 2011

Half-matched transplants widen donor pool for leukemia and lymphoma

7 Jul 2011

Potential new approach for treating myelofibrosis

A new study conducted by a team of researchers at Boston University School of Medicine (BUSM) sheds light on a possible new approach to treat the bone marrow disease known as myelofibrosis by inhibiting an enzyme that connects extracellular fibers.

24 Jun 2011

Angioplasty may be an option for liver transplant candidates with heart disease

A small, retrospective study determined that percutaneous coronary intervention (PCI) was safe in patients with significant coronary artery disease (CAD) who were referred for liver transplantation. Larger studies are needed to determine the effectiveness of angioplasty in patients with end-stage liver disease (ESLD). Details of the study are available in the July issue of Liver Transplantation, published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

22 Jun 2011

Study finds PCI safe and feasible option for End-Stage Liver Disease patients with significant heart disease

22 Jun 2011

ESC publishes position paper to raise the profile of vulnerable plaques

The European Society of Cardiology (ESC) Working Group of Atherosclerosis and Vascular Biology has published a position paper to raise the profile of vulnerable plaques and the need for greater use of therapies to promote plaque stabilisation.

15 Jun 2011

Ilex, Cerus partner to distribute INTERCEPT Blood System in Israel and South Africa

Cerus Corporation today announced today that it has entered into agreements with Ilex Biotech Limited to distribute Cerus' INTERCEPT Blood System for platelets and plasma in South Africa and Israel.

9 Jun 2011

Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be presented at the 47th annual meeting of the American Society of Clinical Oncology in Chicago June 3-7.

24 May 2011

New study sheds light on origins of myeloid leukemia

A new study by the NYU Cancer Institute, an NCI-designated cancer center, sheds light on the origins of myeloid leukemia, a type of blood cancer that affects children and adults.

13 May 2011

AspirinWorks Test now available in greater Boston and surrounding area

A simple urine test that measures aspirin effect is now available in the greater Boston and surrounding area. The AspirinWorks Test is available to eastern Massachusetts and southern New Hampshire area doctors through Diagnostic Laboratory Medicine.

11 May 2011

Researchers find temperature-sensing protein in immune cells

Researchers at The Scripps Research Institute have found a temperature-sensing protein within immune cells that, when tripped, allows calcium to pour in and activate an immune response.

7 May 2011

Tarix begins patient enrollment for TXA127 Phase 1 study in DCBT

Tarix Pharmaceuticals today announced enrollment of the first patient in a Phase 1 clinical study of TXA127, a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow.

27 Apr 2011

America’s best loved drugs: Report

According to the latest report from consulting firm IMS Health, Americans are consuming a lot of prescription drugs. And they seem especially fond of those to lower their cholesterol, relieve heartburn, aid in depressive disorders and lessen pain. Overall, however, their spending on such drugs is slowing.

20 Apr 2011

BioParadox's VitaKine PCT can serve as promising therapy for heart attack patients

BioParadox, Inc., a regenerative medicine company pioneering point-of-care biologic treatments for cardiovascular disease, today announced data supporting the use of VitaKine- Platelet Cell Therapy as a promising treatment for heart attack patients.

8 Apr 2011

Study: Antidepressants can thicken arteries and lead to heart disease

Antidepressant use has been linked to thicker arteries, possibly contributing to the risk of heart disease and stroke, in a study of twin veterans. The data is being presented Tuesday, April 5 at the American College of Cardiology meeting in New Orleans.

4 Apr 2011